Literature DB >> 18692539

Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates.

Igor S Lukashevich1, Ricardo Carrion, Maria S Salvato, Keith Mansfield, Kathleen Brasky, Juan Zapata, Cristiana Cairo, Marco Goicochea, Gia E Hoosien, Anysha Ticer, Joseph Bryant, Harry Davis, Rasha Hammamieh, Maria Mayda, Marti Jett, Jean Patterson.   

Abstract

A single injection of ML29 reassortant vaccine for Lassa fever induces low, transient viremia, and low or moderate levels of ML29 replication in tissues of common marmosets depending on the dose of the vaccination. The vaccination elicits specific immune responses and completely protects marmosets against fatal disease by induction of sterilizing cell-mediated immunity. DNA array analysis of human peripheral blood mononuclear cells from healthy donors exposed to ML29 revealed that gene expression patterns in ML29-exposed PBMC and control, media-exposed PBMC, clustered together confirming safety profile of the ML29 in non-human primates. The ML29 reassortant is a promising vaccine candidate for Lassa fever.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18692539      PMCID： PMC2582173          DOI： 10.1016/j.vaccine.2008.07.057

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  36 in total

Review 1.  Lassa fever.

Authors:  J B McCormick; S P Fisher-Hoch
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

2.  The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P.

Authors:  O Lenz; J ter Meulen; H D Klenk; N G Seidah; W Garten
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

Review 3.  Lassa fever: epidemiology, clinical features, and social consequences.

Authors:  J Kay Richmond; Deborah J Baglole
Journal:  BMJ       Date:  2003-11-29

4.  Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones.

Authors:  Jan ter Meulen; Marlis Badusche; Judith Satoguina; Thomas Strecker; Oliver Lenz; Cornelius Loeliger; Mohamed Sakho; Kekoura Koulemou; Lamine Koivogui; Achim Hoerauf
Journal:  Virology       Date:  2004-03-30       Impact factor: 3.616

5.  Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.

Authors:  P Pushko; J Geisbert; M Parker; P Jahrling; J Smith
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

Review 6.  Hemorrhagic fever viruses as biological weapons: medical and public health management.

Authors:  Luciana Borio; Thomas Inglesby; C J Peters; Alan L Schmaljohn; James M Hughes; Peter B Jahrling; Thomas Ksiazek; Karl M Johnson; Andrea Meyerhoff; Tara O'Toole; Michael S Ascher; John Bartlett; Joel G Breman; Edward M Eitzen; Margaret Hamburg; Jerry Hauer; D A Henderson; Richard T Johnson; Gigi Kwik; Marci Layton; Scott Lillibridge; Gary J Nabel; Michael T Osterholm; Trish M Perl; Philip Russell; Kevin Tonat
Journal:  JAMA       Date:  2002-05-08       Impact factor: 56.272

7.  Hemorrhagic fever occurs after intravenous, but not after intragastric, inoculation of rhesus macaques with lymphocytic choriomeningitis virus.

Authors:  Igor S Lukashevich; Mahmoud Djavani; Juan D Rodas; Juan C Zapata; Amy Usborne; Carol Emerson; Jacque Mitchen; Peter B Jahrling; Maria S Salvato
Journal:  J Med Virol       Date:  2002-06       Impact factor: 2.327

8.  Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein.

Authors:  J ter Meulen; M Badusche; K Kuhnt; A Doetze; J Satoguina; T Marti; C Loeliger; K Koulemou; L Koivogui; H Schmitz; B Fleischer; A Hoerauf
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

9.  Basolateral entry and release of New and Old World arenaviruses from human airway epithelia.

Authors:  Douglas E Dylla; Daniel E Michele; Kevin P Campbell; Paul B McCray
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

10.  Arenavirus-mediated liver pathology: acute lymphocytic choriomeningitis virus infection of rhesus macaques is characterized by high-level interleukin-6 expression and hepatocyte proliferation.

Authors:  Igor S Lukashevich; Ilia Tikhonov; Juan D Rodas; Juan C Zapata; Yida Yang; Mahmoud Djavani; Maria S Salvato
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103
View more
  60 in total

Review 1.  Laboratory Diagnosis of Lassa Fever.

Authors:  Vanessa Raabe; Jeffrey Koehler
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

2.  Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate.

Authors:  Juan C Zapata; Marco Goicochea; Yuka Nadai; Lindsay M Eyzaguirre; Jean K Carr; Luke J Tallon; Lisa Sadzewicz; Garry Myers; Claire M Fraser; Qi Su; Mahmoud Djavani; Igor S Lukashevich; Maria S Salvato
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

3.  Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages.

Authors:  Xavier Carnec; Sylvain Baize; Stéphanie Reynard; Laure Diancourt; Valérie Caro; Noel Tordo; Michèle Bouloy
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

Review 4.  DNA-launched live-attenuated vaccines for biodefense applications.

Authors:  Peter Pushko; Igor S Lukashevich; Scott C Weaver; Irina Tretyakova
Journal:  Expert Rev Vaccines       Date:  2016-04-25       Impact factor: 5.217

5.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

6.  Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines.

Authors:  Benson Yee Hin Cheng; Emilio Ortiz-Riaño; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

Review 7.  VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.

Authors:  Pierre Leblanc; Leonard Moise; Cybelle Luza; Kanawat Chantaralawan; Lynchy Lezeau; Jianping Yuan; Mary Field; Daniel Richer; Christine Boyle; William D Martin; Jordan B Fishman; Eric A Berg; David Baker; Brandon Zeigler; Dale E Mais; William Taylor; Russell Coleman; H Shaw Warren; Jeffrey A Gelfand; Anne S De Groot; Timothy Brauns; Mark C Poznansky
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 8.  The search for animal models for Lassa fever vaccine development.

Authors:  Igor S Lukashevich
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

9.  Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.

Authors:  Ricardo Carrion; Peter Bredenbeek; Xiaohong Jiang; Irina Tretyakova; Peter Pushko; Igor S Lukashevich
Journal:  J Vaccines Vaccin       Date:  2012-11-20

10.  Prevalence and risk factors of Lassa seropositivity in inhabitants of the forest region of Guinea: a cross-sectional study.

Authors:  Solen Kernéis; Lamine Koivogui; N'Faly Magassouba; Kekoura Koulemou; Rosamund Lewis; Aristide Aplogan; Rebecca F Grais; Philippe J Guerin; Elisabeth Fichet-Calvet
Journal:  PLoS Negl Trop Dis       Date:  2009-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.